CTOs on the Move

Cetac Technologies

www.cetac.com

 
Cetac Technologies is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cetac.com
  • 14306 Industrial Rd
    Omaha, NE USA 68144
  • Phone: 800.369.2822

Executives

Name Title Contact Details

Similar Companies

Ology Bioservices

Ology Bioservices is a private, American biopharmaceutical company headquartered in Alachua, Florida.

ArsenalBio

ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy by helping more patients fight cancer and saving lives. Its discovery engine comprises non-viral manufacturing based on its CellFoundry™ technology, integrated circuits incorporating its PrimeR™ logic gates and CAR enhancements from its CARchitecture™ library, enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access.

Muse bio

Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.

ProZyme

ProZyme is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlycoMimetics

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.